BioAge Labs, Inc. (NASDAQ:BIOA) Receives Consensus Recommendation of “Moderate Buy” from Analysts

Shares of BioAge Labs, Inc. (NASDAQ:BIOA) have earned a consensus rating of “Moderate Buy” from the four analysts that are presently covering the stock, MarketBeat Ratings reports. One investment analyst has rated the stock with a sell recommendation and three have given a buy recommendation to the company. The average 12-month target price among brokerages that have issued a report on the stock in the last year is $45.00.

A number of analysts recently issued reports on the company. Oppenheimer assumed coverage on BioAge Labs in a report on Wednesday, February 25th. They issued an “outperform” rating and a $60.00 price target for the company. Piper Sandler initiated coverage on BioAge Labs in a research report on Tuesday, January 27th. They set an “overweight” rating for the company. Citigroup upped their target price on BioAge Labs from $15.00 to $52.00 and gave the stock a “buy” rating in a report on Tuesday, March 10th. Weiss Ratings reissued a “sell (d-)” rating on shares of BioAge Labs in a research report on Tuesday, January 27th. Finally, Morgan Stanley set a $23.00 price target on BioAge Labs in a research note on Wednesday, February 4th.

Insider Activity

In other news, insider Paul D. Rubin sold 7,433 shares of the company’s stock in a transaction that occurred on Monday, February 2nd. The shares were sold at an average price of $18.75, for a total value of $139,368.75. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CEO Kristen Fortney sold 233,107 shares of the stock in a transaction that occurred on Tuesday, January 13th. The shares were sold at an average price of $18.12, for a total transaction of $4,223,898.84. Following the transaction, the chief executive officer owned 976,949 shares in the company, valued at approximately $17,702,315.88. This represents a 19.26% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last quarter, insiders sold 267,540 shares of company stock worth $4,895,168. 20.82% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On BioAge Labs

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Adage Capital Partners GP L.L.C. purchased a new position in shares of BioAge Labs in the 4th quarter worth approximately $13,892,000. Janus Henderson Group PLC purchased a new stake in shares of BioAge Labs during the 4th quarter valued at $5,406,000. Millennium Management LLC lifted its holdings in shares of BioAge Labs by 749.8% during the 3rd quarter. Millennium Management LLC now owns 306,552 shares of the company’s stock valued at $1,803,000 after purchasing an additional 270,479 shares during the last quarter. Sphera Funds Management LTD. acquired a new stake in shares of BioAge Labs in the 4th quarter worth $3,215,000. Finally, Invesco Ltd. acquired a new stake in shares of BioAge Labs in the 4th quarter worth $3,025,000.

BioAge Labs Trading Up 8.7%

NASDAQ BIOA opened at $21.04 on Friday. The stock has a market cap of $754.28 million, a PE ratio of -13.84 and a beta of 1.22. BioAge Labs has a 12 month low of $2.88 and a 12 month high of $24.00. The company’s 50-day moving average price is $20.17 and its 200-day moving average price is $12.45.

BioAge Labs Company Profile

BioAge Labs (NASDAQ: BIOA) is a clinical-stage biotechnology company focused on discovering and developing therapies that address age-associated diseases. The company leverages its proprietary analytics platform to mine large-scale human biological data for insights into the molecular mechanisms of aging. By targeting fundamental aging pathways, BioAge aims to create interventions that extend healthspan and treat conditions that disproportionately affect older populations.

At the core of BioAge’s operations is its integrated drug discovery platform, which combines human omics datasets, machine learning algorithms and experimental validation to identify novel drug targets.